As Biden invokes wartime powers to regulate AI, oncology braces for fundamental change

FDA’s expedited IND pilot aims to shorten the timeline between drug development and first-in-human clinical trials

FDA announced the final design of the Expedited Investigational New Drug Pilot.

September 18, 2026

UNC researchers receive $40M grant to use AI to help develop cancer vaccines

UNC Lineberger Comprehensive Cancer Center has received $40 million from the OpenAI Foundation, the non-profit parent organization that governs the for-profit company OpenAI Group PBC, to generate data that could make personalized cancer vaccines more effective.

September 18, 2026

Vol.52 No.34

In Brief

Texas Oncology collaborates with ACS to promote cancer screening efforts across Texas

Texas Oncology is collaborating with the American Cancer Society to improve access to cancer screening and early detection in Texas through a new, exclusive statewide collaboration. The initiative focuses on breaking down barriers to screening, raising awareness about prevention, and helping more people catch cancer early.

September 18, 2026

Vol.52 No.34

Clinical Roundup

AI may help identify breast cancers missed by mammograms, but clinical benefit remains uncertain, UCLA-led review finds

Artificial intelligence may help radiologists identify subtle signs of breast cancers that are missed during routine mammograms—and some AI systems may even identify patterns associated with an increased risk of cancer before it becomes visible on a mammogram—but there are still many significant limitations, according to a review led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

September 18, 2026

Vol.52 No.34

Clinical Roundup

AI imaging endpoint predicts OS benefit in phase III lung cancer trial: data presented at IASLC WCLC 2026

Altis Labs Inc., the AI endpoint company accelerating clinical trials, on Sept. 17 announced findings from an independent post-hoc analysis evaluating its AI-powered imaging endpoint, IPRO, in the MARIPOSA phase III trial.

September 18, 2026

Vol.52 No.34

Drugs & Targets

FDA approves imlunestrant + abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

FDA approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.

September 18, 2026

Vol.52 No.34

As Biden invokes wartime powers to regulate AI, oncology braces for fundamental change

YOU MAY BE INTERESTED IN

FDA’s expedited IND pilot aims to shorten the timeline between drug development and first-in-human clinical trials

UNC researchers receive $40M grant to use AI to help develop cancer vaccines

Texas Oncology collaborates with ACS to promote cancer screening efforts across Texas

AI may help identify breast cancers missed by mammograms, but clinical benefit remains uncertain, UCLA-led review finds

AI imaging endpoint predicts OS benefit in phase III lung cancer trial: data presented at IASLC WCLC 2026

FDA approves imlunestrant + abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login